Please login to the form below

Not currently logged in
Email:
Password:

CDK4/6 inhibitor

This page shows the latest CDK4/6 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Lilly boosted by survival data for key growth drug Verzenio

Lilly boosted by survival data for key growth drug Verzenio

New results from the MONARCH 2 trial have shown that the CDK4/6 inhibitor achieved a statistically significant improvement in overall survival in pre-, peri- and post-menopausal women with advanced, ... However, shortly after the top-line data were

Latest news

  • NICE nod for Lilly’s breast cancer drug Verzenio via CDF NICE nod for Lilly’s breast cancer drug Verzenio via CDF

    Helps Lilly drug in pursuit of Ibrance and Kisqali. Thousands of women with advanced breast cancer could get access to treatment with Eli Lilly’s CDK 4/6 inhibitor Verzenio, after ... $6bn product at peak by EvaluatePharma – as well as Novartis’

  • NICE gives Lilly’s Verzenios chance to compete with rivals NICE gives Lilly’s Verzenios chance to compete with rivals

    CDK4/6 inhibitor class. ... Around 46, 000 women are diagnosed with breast cancer each year in England and Wales, of whom around 8, 000 would be eligible for treatment with a CDK4/6 inhibitor.

  • CHMP backs Sanofi’s all-oral sleeping sickness drug CHMP backs Sanofi’s all-oral sleeping sickness drug

    Among these, Novartis’ CDK4/6 inhibitor Kisqali (ribociclib) was recommended for the treatment of women with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in combination with fulvestrant

  • Novartis claims a rare win at ESMO for PI3K inhibitor class Novartis claims a rare win at ESMO for PI3K inhibitor class

    16%. Alpelisib was also fairly well tolerated in the 572-patient study, which involved patients whose disease had progressed after earlier treatment with an aromatase inhibitor with or without a ... 6 inhibitor, a newer drug group which includes

  • Lilly gets EMA nod for Verzenio in breast cancer Lilly gets EMA nod for Verzenio in breast cancer

    Eli Lilly has the approval it was looking for in Europe for CDK4/6 inhibitor Verzenio, allowing to challenge rivals from Pfizer and Novartis in breast cancer. ... women. It’s not all been plain sailing for Lilly’s CDK4/6 inhibitor programme however.

More from news
Approximately 2 fully matching, plus 23 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

The big issue
Whether you want to lead or follow, you need to understand the elephant in the C-suite...
INFOGRAPHIC 02: The Importance of clinical study websites
Here’s a infographic of why clinical study websites are important to patient recruitment and retention strategies…...
Working with, Advocating for, and Empowering Patients
A holistic view of how to work with patients virtually...

Infographics